These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25623397)

  • 1. Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults.
    Wieland I; Kentouche K; Jentzsch M; Lothschütz D; Graf N; Sykora KW
    Pediatr Blood Cancer; 2015 May; 62(5):823-9. PubMed ID: 25623397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
    Stein GY; Blickstein D; Orlin J; Sarig G; Inbal A
    Isr Med Assoc J; 2011 Jul; 13(7):398-401. PubMed ID: 21838180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.
    Ling HT; Field JJ; Blinder MA
    Am J Hematol; 2009 Jul; 84(7):418-21. PubMed ID: 19507208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
    Chemnitz JM; Uener J; Hallek M; Scheid C
    Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.
    Jayabose S; Dunbar J; Nowicki TS; Tugal O; Ozkaynak MF; Sandoval C
    Pediatr Hematol Oncol; 2011 Mar; 28(2):167-72. PubMed ID: 20469972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.
    Bhagirath VC; Kelton JG; Moore J; Arnold DM
    Transfusion; 2012 Dec; 52(12):2517-23. PubMed ID: 22486316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
    Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
    Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.
    Aqui NA; Stein SH; Konkle BA; Abrams CS; Strobl FJ
    J Clin Apher; 2003; 18(2):51-4. PubMed ID: 12874815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura.
    Patino W; Sarode R
    J Clin Apher; 2007 Feb; 22(1):17-20. PubMed ID: 17285618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
    Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
    Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura].
    Cui J; Zhu TN; Zou N; Chen M; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):116-20. PubMed ID: 23469801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura].
    Curtillet C; Poullin P; Doré E; Fossat C; Lefevre P; Michel G
    Arch Pediatr; 2006 Dec; 13(12):1521-4. PubMed ID: 17010579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab.
    Clark WF; Rock G; Barth D; Arnold DM; Webert KE; Yenson PR; Kelton JG; Li L; Foley SR;
    Br J Haematol; 2015 Jul; 170(2):208-17. PubMed ID: 25855259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
    Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura.
    Chen H; Fu A; Wang J; Wu T; Li Z; Tang J; Shen H; Zhu J; Li J; Zhu Q; Qing L
    J Int Med Res; 2017 Jun; 45(3):1253-1260. PubMed ID: 28639502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel.
    Rinott N; Mashiach T; Horowitz NA; Schliamser L; Sarig G; Keren-Politansky A; Dann EJ
    Acta Haematol; 2015; 134(3):170-6. PubMed ID: 25997685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
    Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.